In-vitro fertilization (IVF), which accounts for 1% to 2% of all births in the nation, may benefit from the use of artificial intelligence (AI), which could assist fertility specialists in choosing the best embryo.
By deploying AI-powered embryo evaluation software called EMA, AIVF, a reproductive technology business with headquarters in Tel Aviv, Israel, seeks to increase the likelihood that IVF will be successful.
The best IVF embryos
The program streamlines the embryo selection process by processing enormous amounts of data beyond what the human eye can see. AI has been trained to recognize aspects of the embryo that are invisible to the human eye but are associated with certain outcomes, such as genetic anomalies, implantation, or gender.
AI helps clinicians make the key choice about embryo selection while lowering uncertainties and generating precise, understandable data. Additionally, because the AI evaluates embryos more quickly than a person, clinics can visit more patients and handle higher demand.
- AI could improve in-vitro fertilization for optimal embryo selection.
- AI streamlines embryo selection by recognizing invisible aspects of embryos.
- AIVF technology in South America, Asia, Europe, US accessible soon.
The ‘eye’ of AI may be on developing children, and it may be able to foretell preterm birth as early as 31 weeks. Dr. Shahin Ghadir, a California-based Trimly fertility coach, and double board-certified infertility specialist, thinks AI technology like AIVF could be beneficial.
He emphasized that while AI can assist clinicians in evaluating embryos, consulting with patients, and providing better IVF care, it is not meant to completely replace doctors. Ghadir emphasized that before it is implemented, AI must be “scrutinized under significant criteria.”
The technology behind AIVF is already in use in South America, Southeast Asia, and Europe and is anticipated to become accessible in the United States “very soon.”
Clinics have reported a 30% rise in IVF success rates, and the technology may result in viable pregnancies in less time, which might lower the cost to the patient.
